Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Operating Income

Profit from core operations after operating expenses, before interest and taxes.

Biohaven Ltd.NYSE: BHVN

Operating Income · Q2 FY2026 · quarter ended Jun 2026

Operating income remains negative

Q2 FY2026 operating income was -$124.9M, compared with -$211.7M a year earlier. Trailing-twelve-month operating income was -$567.44M.

Context

  • Operating income grew in size in 1 of the last 3 fiscal years.

What to watch

Whether operating income reaches the consensus estimate from 8 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +15.8% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$124.9M+4.2% QoQ
Last fiscal yearDec 2025
-$745.38M+15.8% YoY
LTMJun 2026
-$567.44M+29.2% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+41.0%+100.0%+59.0 pp
1 year+15.8%+100.0%+84.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(745.38M) USD
Year-over-year change
+15.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +29.2% is the 3rd highest of 11, against a peer median of -28.4%.
BHVN Competitors
Operating Income for BHVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$35.9M USD+259.6%—11.4%
IMCRImmunocore Holdings plcLTM Mar 2026-$29.36M USD+38.3%—7.6%
SIONSionna Therapeutics, Inc.LTM Mar 2026-$98.92M USD-28.4%——
PHVSPharvaris N.V.LTM Sep 2026-€193.47M EUR-125.1%——
ABCLAbCellera Biologics Inc.LTM Sep 2026-$202.19M USD+22.6%—298.0%
IMNMImmunome, Inc.LTM Sep 2026-$300.69M USD-28.4%——
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$334.5M USD-30.5%—298657.1%
VERAVera Therapeutics, Inc.LTM Jun 2026-$415.76M USD-76.1%——
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-$420.72M USD+22.2%—636.6%
ZBIOZenas BioPharma, Inc.LTM Mar 2026-$423.08M USD-143.7%——
BHVNBiohaven Ltd.LTM Jun 2026-$567.44M USD+29.2%——
Peer median (excluding BHVN) —-28.4%—298.0%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.14M
Gross Profit0000(4.14M)
Gross Margin—————
Research & Development181.49M437.07M373.28M795.87M635.07M
Selling, General & Admin37.41M130.86M62.77M89.24M106.17M
Operating Expenses218.9M567.93M436.05M885.11M741.24M
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
EBITDA(211.04M)(568.46M)(402.64M)(837.83M)(727.46M)
EBITDA Margin—————
Operating Income(218.9M)(567.93M)(436.05M)(885.11M)(745.38M)
Operating Margin—————
Interest Income0017.73M21.33M14.59M
Interest Expense00000
Other Income / Expenses6.47M(1.91M)26.5M39.42M8M
Income Before Tax(212.43M)(569.84M)(409.55M)(845.69M)(737.38M)
Pre-Tax Margin—————
Income Tax Expense1.37M438K(1.38M)735K1.44M
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Net Margin—————
EPS (Basic)(5.97)(12.75)(5.73)(9.28)(6.86)
EPS (Diluted)(5.97)(12.75)(5.73)(9.28)(6.86)
Weighted Avg Shares35.82M44.74M71.2M91.23M107.62M
Weighted Avg Shares (Diluted)35.82M44.74M71.2M91.23M107.62M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.